The Effect of Preoperative SGB on POAF After VATS
Atrial Fibrillation
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring Postoperative atrial fibrillation, stellate ganglion block
Eligibility Criteria
Inclusion Criteria: 1.patients undergoing elective thoracoscopic lobectomy; 2.patients with one or more risk factors of POAF. According to literature, risks factors of POAF including male, aged over 65, obesity (BMI>30kg/m2), cardiac co-morbidity ( hypertension, myocardial infarction, heart failure, arrhythmia, history of valve procedure), diabetes, chronic renal insufficiency (increased creatinine level), obstructive sleep apnea syndrome (diagnosed or STOP-BANG scores ≥3). Exclusion Criteria: 1. patients with permanent atrial fibrillation, left ventricular or right ventricular pacemaker implantation or removal; 2. patients use antiarrhythmic drugs (except beta-blockers); 3.patients use immunosuppressive drugs preoperatively; 4.patients with active infection or sepsis; 5. patients with neurologic disorder; 6.patients with immune deficiency syndrome.
Sites / Locations
- Peking University People's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
SGB group
control group
The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.
The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.